Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.48 |
| ▸ | MLYCD | O95822 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL947922 | 0.88 | FAAH (0.53) | CASP2NAAAEPHX2RECQLFAAH | |
| SCHEMBL1709282 | 0.87 | MEN1 (0.48) | MLYCDHPGDEPHX2RECQLGAA | |
| SCHEMBL7099277 | 0.86 | FAAH (0.56) | CASP2NAAAEPHX2FAAHGAA | |
| SCHEMBL30271864 | 0.84 | CASP2 (0.41) | CASP2HPGDEPHX2 | |
| SCHEMBL8596100 | 0.84 | ECE1 (0.40) | MLYCDEPHX2RECQLFAAHGAA | |
| SCHEMBL30111127 | 0.84 | EPHX2 (0.49) | CASP2MLYCDHDAC8EPHX2RECQL | |
| SCHEMBL27426198 | 0.84 | MLYCD (0.39) | MLYCDHPGDEPHX2RECQLGAA | |
| SCHEMBL8531447 | 0.84 | TSHR (0.46) | MLYCDHPGDEPHX2RECQL | |
| SCHEMBL6184206 | 0.84 | EPHX2 (0.40) | MLYCDHPGDNAAAEPHX2RECQL | |
| SCHEMBL6184198 | 0.84 | EPHX2 (0.40) | MLYCDHPGDEPHX2RECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-04 | — | — | US | disclosed |
| EP-1564213-A1 | IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | HRH4, F2, HRH2 | CASP2 761/4885MLYCD 1754/4885HPGD 356/4885 |
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | F2, H1-3, CYC1 | CASP2 1024/4885MLYCD 1963/4885HPGD 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.